Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
about
Prion diseases: immunotargets and therapyDiagnosis and evaluation of a patient with rapidly progressive dementiaCalcineurin inhibition at the clinical phase of prion disease reduces neurodegeneration, improves behavioral alterations and increases animal survivalSystematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditionsAnti-prion activity of a panel of aromatic chemical compounds: in vitro and in silico approachesBeyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancersInvolvement of consumers in studies run by the Medical Research Council Clinical Trials Unit: results of a survey.Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease.MRI findings are often missed in the diagnosis of Creutzfeldt-Jakob diseaseFrom high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease.High-b-value diffusion MR imaging and basal nuclei apparent diffusion coefficient measurements in variant and sporadic Creutzfeldt-Jakob disease.Brain-water diffusion coefficients reflect the severity of inherited prion disease.Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.Coinfecting prion strains compete for a limiting cellular resource.Postmortem findings in a case of variant Creutzfeldt-Jakob disease treated with intraventricular pentosan polysulfate.Population screening for variant Creutzfeldt-Jakob disease using a novel blood test: diagnostic accuracy and feasibility study.Pharmacological chaperone for the structured domain of human prion protein.Activation of pro-survival CaMK4β/CREB and pro-death MST1 signaling at early and late times during a mouse model of prion disease.The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases.Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease.Cellular and molecular actions of Methylene Blue in the nervous systemVariant CJD. 18 years of research and surveillance.Review: contribution of transgenic models to understanding human prion disease.Structure-based drug design identifies polythiophenes as antiprion compounds.PRION-1 scales analysis supports use of functional outcome measures in prion disease.Genome-wide association study of behavioural and psychiatric features in human prion disease.Rapidly progressive dementias and the treatment of human prion diseases.Polythiophenes inhibit prion propagation by stabilizing prion protein (PrP) aggregates.Antiprion Activity of DB772 and Related Monothiophene- and Furan-Based Analogs in a Persistently Infected Ovine Microglia Culture SystemQuinacrine induced mood disturbance--the unmasking of bipolar affective disorder.Discovery of Novel Anti-prion Compounds Using In Silico and In Vitro ApproachesIatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years.Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1.A Single Subcutaneous Injection of Cellulose Ethers Administered Long before Infection Confers Sustained Protection against Prion Diseases in RodentsTranslational research in neurology: dementia.Therapies for human prion diseasesEthics in prion disease.Multiparameter MR imaging in the 6-OPRI variant of inherited prion disease.Prion disease: experimental models and reality.Doxycycline in early CJD: a double-blinded randomised phase II and observational study.
P2860
Q26741258-746AFFED-83FF-44F2-8870-D6FBB56EEE90Q26822666-7A5D8380-FF06-4799-BEAB-F3B6161AB108Q27313215-3D4F3C67-D4DE-4075-AF22-BF18CB4E7F1AQ28075766-D6DAB7EC-FD75-4ED6-B202-893EA798172EQ28538336-FBBA1796-6537-400F-8DE9-65D815BBF5E1Q28743513-8356825A-82A5-458F-B0FA-4B70647B4B71Q30520643-55E38838-6AF8-4CAB-8AE1-E9AEC05C7DFDQ30540027-E2A00425-F83B-4B2A-BE28-8C28CDDE7687Q30580383-8A39371C-0CE2-442E-9487-7A98FF520B23Q31023317-215ED14E-65C2-4363-8B00-3B89ED97E828Q33518254-5A96DBD6-D601-4F90-A573-81A376EDFA48Q33533558-2ECCFA1D-2FA7-497F-9BDF-3FD5F59C68B1Q33560026-335B8456-5443-496F-A34C-756913119D3EQ33877386-EFE552F1-65C0-47B4-8270-1EF56ECB6934Q33956775-AE9AA62A-8BEB-48C7-82BE-E7C6AFFCD714Q34153674-DD25211A-1E7E-401B-86A3-22CE2D5622B3Q34199756-B1101EC6-183C-4FB2-9AAC-56A9FF5E3D78Q34207678-9038C542-0620-4206-90F6-F8700F6D185AQ34286572-29C53FFF-BDB8-45E6-A4EA-97E5F6349B89Q34415659-AAC33585-F346-4EF2-B747-B718C44C386AQ34422385-EA585365-FC57-45CC-979C-43770843688EQ34453109-7614B8D3-EC48-4C16-9A01-9E86498F5DA1Q34474868-909BC3CE-8A88-4299-BA17-E87A7420A4E7Q34488418-5E8F54D1-4FBE-4745-A464-2E602EF6AD30Q35529970-13A4E63C-B672-4CE0-8840-5317AA29B551Q35715185-795F6105-1FE6-424A-A9B2-AF39D03B4387Q35832931-13EDF8E5-A610-4252-950C-E01710D221A6Q36003595-F3E12FA5-82E3-4B3B-907B-D571EA2653C9Q36068573-86B0F723-3B43-4E0A-B909-64247D5C2A4CQ36069944-5F7E1F6F-0C93-4D6F-AB9F-45CC5F25F8CFQ36139197-F712AC8C-1968-4B51-8B13-37853FF9350DQ36206020-AA83B95B-FC07-4220-A459-9D02474AF1E9Q36213835-D414F60C-3126-4837-B9A4-030B7A196C84Q36223572-859B022F-CFB0-4504-AADB-E38C3EE8DECFQ36817161-73553058-AACB-4878-98EB-1E7E4E201049Q37199225-ECCE35DE-B7C5-481D-B049-A67091D6E5F0Q37282279-CB8C718A-603D-4BDC-BFEB-0A031859E19BQ37328569-369DCB36-9F12-4D1A-8A2D-B93E2AF98952Q37596801-485D62D9-8C0C-4784-8B99-669CFB3DD874Q37617090-75913298-F7DE-4408-9A1E-6CA4C5BF57FB
P2860
Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Safety and efficacy of quinacr ...... y): a patient-preference trial
@ast
Safety and efficacy of quinacr ...... y): a patient-preference trial
@en
Safety and efficacy of quinacr ...... y): a patient-preference trial
@nl
type
label
Safety and efficacy of quinacr ...... y): a patient-preference trial
@ast
Safety and efficacy of quinacr ...... y): a patient-preference trial
@en
Safety and efficacy of quinacr ...... y): a patient-preference trial
@nl
prefLabel
Safety and efficacy of quinacr ...... y): a patient-preference trial
@ast
Safety and efficacy of quinacr ...... y): a patient-preference trial
@en
Safety and efficacy of quinacr ...... y): a patient-preference trial
@nl
P2093
P2860
P50
P3181
P1433
P1476
Safety and efficacy of quinacr ...... y): a patient-preference trial
@en
P2093
Angus Kennedy
Dafydd Thomas
Durre Siddique
Fleur Hudson
Geraldine Keogh
John Collinge
Michele Gorham
Moira Spyer
Peter Rudge
Sarah Walker
P2860
P304
P3181
P356
10.1016/S1474-4422(09)70049-3
P407
P577
2009-04-01T00:00:00Z